Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance

Int J Mol Sci. 2018 Dec 23;20(1):51. doi: 10.3390/ijms20010051.

Abstract

Histone modification is associated with resistance to anti-cancer drugs. Epigenetic modifications of histones can regulate resistance to anti-cancer drugs. It has been reported that histone deacetylase 3 (HDAC3) regulates responses to anti-cancer drugs, angiogenic potential, and tumorigenic potential of cancer cells in association with cancer-associated genes (CAGE), and in particular, a cancer/testis antigen gene. In this paper, we report the roles of microRNAs that regulate the expression of HDAC3 and CAGE involved in resistance to anti-cancer drugs and associated mechanisms. In this review, roles of HDAC3-miRNAs-CAGE molecular networks in resistance to anti-cancer drugs, and the relevance of HDAC3 as a target for developing anti-cancer drugs are discussed.

Keywords: anti-cancer drug-resistance; cancer/testis antigen CAGE; epidermal growth factor receptor; histone deacetylase-3; micro RNAs; molecular network.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • DEAD-box RNA Helicases / metabolism*
  • Drug Resistance, Neoplasm*
  • Epigenesis, Genetic
  • Histone Deacetylases / metabolism*
  • Histones / drug effects
  • Humans
  • MicroRNAs / metabolism*
  • Neoplasms / drug therapy
  • Neoplasms / enzymology*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / enzymology

Substances

  • Antineoplastic Agents
  • Histones
  • MicroRNAs
  • Histone Deacetylases
  • histone deacetylase 3
  • DDX53 protein, human
  • DEAD-box RNA Helicases